- Verona Pharma has entered into a global strategic services agreement with QuintilesIMS, a provider of biopharmaceutical development and commercial outsourcing services.

The agreement establisheD an operational platform to facilitate Verona Pharma's global clinical trial-related activities for the development of its product candidate RPL554 for the treatment of COPD (chronic obstructive pulmonary disease) and cystic fibrosis and for future commercialisation initiatives.

Quintiles would serve as sole provider of core clinical trial services for Verona Pharma's RPL554 clinical development programmes.

Verona Pharma would have full access to Quintiles' therapeutic and operational experts throughout the duration of each trial, from the planning and design through to execution.

Joint governance and quality oversight has been established to ensure strategic and operational goals were met and compliance with regulatory and quality requirements.

Verona Pharma would also have access to QuintilesIMS' global commercial insights when developing its market access strategy in the US for RPL554.

Story provided by